CCDC88B

CCDC88B is a cytoskeleton-associated scaffold protein that functions as a central regulator of immune cell activation, migration, and cytotoxicity. In T lymphocytes, CCDC88B is required for TCR-dependent activation, proliferation, and cytokine production (IFN-γ, TNF), and its loss confers protection from inflammatory bowel disease in both chemical and T cell transfer colitis models (PMID:25403443, PMID:29030607). In dendritic cells and NK cells, CCDC88B controls cell motility and effector function: it binds microtubules and the dynein motor complex to direct MTOC polarization and lytic granule clustering in NK cells, and forms a ternary complex with ARHGEF2 and RASAL3 that modulates RHOA activation to drive DC migration to draining lymph nodes (PMID:25762780, PMID:32480428, PMID:38200184). CCDC88B also functions at the endoplasmic reticulum, where it interacts with GRP78 to stabilize the GRP78–IRE1 complex, attenuating JNK signaling and protecting cells from ER stress-induced apoptosis (PMID:21289099, PMID:25792451).

1. 2011 High

   Identifying CCDC88B (Gipie) as an ER stress-protective factor resolved how cells fine-tune IRE1-JNK signaling: Gipie stabilizes the GRP78–IRE1 complex, attenuating JNK activation and apoptosis under ER stress.

   Evidence Co-IP of Gipie with GRP78/IRE1 in endothelial cells; siRNA knockdown showing increased JNK phosphorylation and apoptosis; rat carotid balloon injury model

   PMID:21289099

   Open questions at the time

   • Whether CCDC88B's ER-stress role operates in immune cells remains untested
   • Structural basis for CCDC88B–GRP78 interaction is undefined
   • Relationship between ER-stress and cytoskeletal functions of CCDC88B is unclear
2. 2014 High

   An unbiased ENU screen revealed CCDC88B as essential for T cell activation, proliferation, and cytokine production, establishing it as a previously unknown regulator of adaptive immunity and pathological inflammation.

   Evidence Ccdc88b loss-of-function mutant mice; in vitro T cell stimulation with TCR or PMA/ionomycin; P. berghei infection model; flow cytometry

   PMID:25403443

   Open questions at the time

   • Proximal signaling events downstream of TCR that require CCDC88B are uncharacterized
   • Whether CCDC88B acts in CD8+ versus CD4+ T cells with distinct mechanisms is unknown
3. 2015 High

   Demonstrating that CCDC88B binds microtubules and the dynein complex and directs MTOC polarization and lytic granule clustering established the mechanistic basis for its role in NK cell cytotoxicity.

   Evidence Co-IP with dynein, microtubule co-sedimentation assay, subcellular fractionation for lytic granules, siRNA knockdown in NK cells with cytotoxicity and immunofluorescence readouts

   PMID:25762780

   Open questions at the time

   • Which dynein subunit(s) CCDC88B directly contacts is not mapped
   • Whether the microtubule-binding and ER-stress functions are mutually exclusive or context-dependent is unresolved
4. 2015 Medium

   Extension of CCDC88B's ER-stress function to vascular smooth muscle cells showed that Gipie controls VSMC survival and neointimal thickening through JNK modulation, generalizing the ER-stress mechanism beyond endothelial cells.

   Evidence siRNA knockdown and overexpression in VSMCs; JNK phosphorylation and apoptosis assays; rat carotid artery balloon injury with histomorphometry

   PMID:25792451

   Open questions at the time

   • Findings from a single lab; independent replication in other vascular injury models is lacking
   • Whether CCDC88B modulates collagen maturation directly or through apoptosis reduction is unresolved
5. 2017 High

   Demonstrating that Ccdc88b-deficient mice resist colitis and that mutant CD4+ T cells fail to transfer disease established a cell-intrinsic requirement for CCDC88B in inflammatory bowel disease pathogenesis.

   Evidence DSS-induced colitis and CD4+ T cell adoptive transfer colitis models in Ccdc88b-deficient mice; histopathology and cytokine quantification

   PMID:29030607

   Open questions at the time

   • Whether CCDC88B contributes to colitis through migration, activation, or both is not dissected
   • Human genetic association with IBD is not demonstrated
6. 2020 High

   Showing that CCDC88B is required for DC motility and in vivo migration to draining lymph nodes extended its immune role beyond T and NK cells, positioning it as a general regulator of immune cell migration.

   Evidence In vivo DC migration assay (LPS challenge), OVA-pulsed DC injection with T cell readout, time-lapse microscopy of WT vs. mutant DCs, contact hypersensitivity model

   PMID:32480428

   Open questions at the time

   • The cytoskeletal or signaling pathway through which CCDC88B drives DC motility was not identified at this stage
7. 2024 High

   Identification of a CCDC88B/ARHGEF2/RASAL3 complex that modulates RHOA activation provided the long-sought signaling mechanism underlying CCDC88B-dependent DC migration and linked it to neuroinflammation and colitis.

   Evidence Co-IP and mass spectrometry; Arhgef2 and Rasal3 KO mouse models; RHOA-GTP pull-down; DC motility assays; EAE and colitis models

   PMID:38200184

   Open questions at the time

   • How CCDC88B scaffolds ARHGEF2 and RASAL3 structurally is unknown
   • Whether the RHOA-regulatory complex operates in T cells and NK cells to explain their CCDC88B-dependent phenotypes is untested
   • Upstream signals that regulate assembly of the ternary complex are undefined

• How CCDC88B's two major functions — cytoskeletal scaffolding for immune cell migration/cytotoxicity and ER-stress attenuation via GRP78–IRE1 — are coordinated or segregated across cell types remains an open question.
• No study has examined both ER-stress and cytoskeletal functions in the same cell type or experimental system
• Whether CCDC88B's microtubule-binding domain and GRP78-interacting regions are separable has not been tested with domain mutants
• Direct evidence for CCDC88B function in human immune cells (as opposed to mouse) is lacking